/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Gamma-glutamyl Transferase and insulin resistance. Various effects of RAS-blockade plus CCB combination: results from a randomized 12-week open-label comparative study
Event: ESC Preventive Cardiology 2023
Topic: Pharmacotherapy
Session: Moderated ePoster 3
Target attainment of Blood Pressure goals with RAS-blockers plus CCB, according to ESC 2018 and 2021 guidelines. Results from a randomized 12-week open-label comparative study
Event: ESC Preventive Cardiology 2023
Topic: Epidemiology, Prognosis, Outcome
Session: Moderated ePoster 3
Indices of renal function alternation with RAS-blockers plus CCB combinations: a randomized 12-week open-label comparative study
Event: ESC Preventive Cardiology 2023
Topic: Pharmacotherapy
Session: Moderated ePoster 3
Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
Event: ESC Congress 2022
Topic: Pharmacotherapy
Session: Hypertension - Pharmacotherapy
Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with manidipine/delapril in prediabetic hypertensive patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients
Event: ESC Preventive Cardiology 2022
Topic: Pharmacotherapy
Session: ePosters
ESC 365 is supported by
